$BABY (Natus Medical Inc.)

$BABY {{ '2016-01-11T22:26:57+0000' | timeago}} • Announcement

$BABY said that it expects to report revenue of approx. $100MM for 4Q15, compared to prior guidance of $102-105MM and full year 2015 revenue of $375.9MM compared to prior guidance of $378-381MM. The guidance provided in Oct. 2015 for 4Q15 included expected revenue of approx. $4MM under the new Venezuelan Ministry of Health contract.

$VAR {{ '2017-07-27T13:52:33+0000' | timeago}} • Announcement

Medical devices company $VAR has entered into a strategic collaboration with PetCure Oncology for the treatment of pets suffering from cancer. Under the partnership, Varian's software suite will be deployed across PetCure's veterinary cancer care centers. PetCure will acquire six Varian Halcyon treatment systems for use in select sites in the US.

$REGN {{ '2017-07-21T15:50:38+0000' | timeago}} • Announcement

$REGN and $SNY announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has given a positive opinion for the marketing authorization of Dupixent (dupilumab), recommending its approval in Europe for use in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.

$HRC {{ '2017-07-19T14:11:03+0000' | timeago}} • Announcement

$HRC declared a dividend of $0.18 per share for 4Q17 payable on September 29, 2017, to shareholders of record as of September 15, 2017. The indicated annual dividend rate is $0.72 per share.

$LIVN {{ '2017-07-12T12:45:32+0000' | timeago}} • Announcement

$LIVN appointed Keyna Skeffington as SVP and General Counsel. Skeffington most recently served as Vice President of Legal – Corporate and Securities, Deputy General Counsel and Assistant Secretary at $MDT.

$VAR {{ '2017-07-11T12:14:17+0000' | timeago}} • Announcement

$VAR begins advanced breast cancer treatments using Edge radiosurgery system in combination with respiratory gating. The Edge radiosurgery system enables clinicians to attack tumors from outside the body using carefully shaped high-energy X-rays.

$MDT {{ '2017-07-10T15:43:07+0000' | timeago}} • Announcement

$MDT announced the expanded FDA approval of the self-expanding CoreValve Evolut transcatheter aortic valve replacement platform to include patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-heart surgery.

$MTD {{ '2017-07-05T13:49:43+0000' | timeago}} • Announcement

$MTD said Elisha Finney has been appointed to its BoD and Audit Committee, effective November 1, 2017. It is anticipated that Finney will succeed Francis Contino as the Chair of the Audit Committee upon his retirement in May 2018. Finney served as the CFO of $VAR.

$MASI {{ '2017-06-30T12:41:36+0000' | timeago}} • Announcement

Medical technology firm $MASI entered into a partnership with Midmark Corp. for enhancing the accuracy and efficiency of vital signs acquisition in the clinical space. Under the deal, Masimo’s SET pulse oximetry technology is an available option with Midmark's IQvitals Zone. The combination provides accurate and real-time vital signs information.

$VAR {{ '2017-06-29T13:48:54+0000' | timeago}} • Announcement

$VAR has received both FDA 510(k) clearance and CE mark for its Halcyon system, the company's new device for cancer treatment.

$VAR {{ '2017-06-29T13:28:06+0000' | timeago}} • Announcement

$VAR said it received FDA clearance for its cancer treatment device Halcyon, which enhances image-guided volumetric intensity modulated radiotherapy. The system is designed to accelerate installation timeframes, expedite commissioning and automate treatment.

$MDT {{ '2017-06-23T12:04:14+0000' | timeago}} • Announcement

$MDT has announced a 7% increase in its quarterly cash dividend, raising the amount to $0.46 per ordinary share. The dividend is payable on July 26, 2017, to shareholders of record as of July 7, 2017.

$MMSI {{ '2017-06-22T16:08:44+0000' | timeago}} • Announcement

$MMSI received 513(f)(2) (de novo) classification from the FDA to expand indication for $MMSI's Embosphere Microspheres. The indication now includes prostatic artery embolization (PAE) for symptomatic benign prostatic hyperplasia (BPH).

$VAR {{ '2017-06-22T15:41:36+0000' | timeago}} • Announcement

$VAR delivered the cyclotron, a particle accelerator which accelerates protons to two-thirds the speed of light for clinical use, to UK's Christie Proton Therapy Center.

$VAR {{ '2017-06-21T12:39:55+0000' | timeago}} • Announcement

$VAR said it is working with Sify Technologies to provide software-as-a-service (SaaS) to radiotherapy centers across India. The innovative service is being implemented as part of a multi-million dollar investment in treatment equipment and software across Cancer Treatment Services International network of cancer hospitals in India and South Asia.

$MDT {{ '2017-06-20T13:54:51+0000' | timeago}} • Announcement

$MDT said data from a recent study showed that its cardiac resynchronization therapy devices reduced healthcare system costs and improved therapy delivery in heart failure patients. A European health-economic analysis indicated that Medtronic’s AdaptivCRT extended life expectancy of patients by about four months, while lowering healthcare costs.

$SYK {{ '2017-06-19T12:28:25+0000' | timeago}} • Announcement

$SYK agreed to buy $NVDQ. The transaction is expected to be dilutive to $SYK's 2017 adjusted EPS by $0.03-0.05. There is no change in $SYK's 2017 adjusted EPS forecast of $6.35-6.45. For 2018, this transaction is expected to be neutral to $SYK's earnings and accretive thereafter.

$SYK {{ '2017-06-19T12:26:47+0000' | timeago}} • Announcement

$SYK agreed to buy $NVDQ for $11.75 per share, or $701MM with a net purchase price of $654MM, reflecting net cash of about $47MM. The transaction is expected to close at the end of 3Q17.

$MDT {{ '2017-06-19T11:01:15+0000' | timeago}} • Announcement

$MDT said its Reactive ATP therapy slows the progression of atrial fibrillation (AF) in patients with implanted cardiac devices. A robust, real-world analysis of nearly 8,800 patients was presented as a late breaking clinical trial at EHRA Europace-Cardiostim 2017.

$GE {{ '2017-06-14T12:04:29+0000' | timeago}} • Announcement

$GE's GE Additive and $SYK have entered a partnership agreement to support $SYK's growth in additive manufacturing. The agreement covers new additive machines, materials and services for $SYK's global supply chain operations.

$CNMD {{ '2017-06-13T18:31:27+0000' | timeago}} • Announcement

$CNMD said it will pay a cash dividend of $0.2 per share on July 05, 2017. Shareholders who purchased Conmed Corp. stock prior to the ex-dividend date of June 13, 2017, are eligible for the dividend payment.

Recent Transcripts

SYK (Stryker Corporation)
Thursday, July 27 2017 - 8:30pm
MMSI (Merit Medical Systems, Inc.)
Wednesday, July 26 2017 - 9:00pm
VAR (Varian Medical Systems, Inc.)
Wednesday, July 26 2017 - 9:00pm
CNMD (CONMED Corporation)
Wednesday, July 26 2017 - 8:30pm
BABY (Natus Medical Inc.)
Wednesday, July 26 2017 - 3:00pm
CHE (Chemed Corp.)
Wednesday, July 26 2017 - 2:00pm
NURO (NeuroMetrix Inc.)
Thursday, July 20 2017 - 12:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
ELMD (Electromed, Inc.)
Tuesday, May 16 2017 - 1:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
RMTI (Rockwell Medical, Inc.)
Tuesday, May 9 2017 - 8:30pm
NXTM (Nxstage Medical, Inc.)
Tuesday, May 9 2017 - 1:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
IRIX (IRIDEX Corporation)
Wednesday, May 3 2017 - 9:30pm
MASI (Masimo Corporation)
Wednesday, May 3 2017 - 8:30pm
NVDQ (Novadaq Technologies Inc.)
Wednesday, May 3 2017 - 8:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, April 28 2017 - 12:30pm
MMSI (Merit Medical Systems, Inc.)
Thursday, April 27 2017 - 9:00pm
SPNC (The Spectranetics Corporation)
Thursday, April 27 2017 - 8:30pm
CHE (Chemed Corp.)
Thursday, April 27 2017 - 2:00pm

AlphaGraphics you may like